ProZinc Insulin for Cats
- Veterinarian Prescription (Rx) Required
- Must Ship Overnight
- Low Price Match Guarantee
- Protamine zinc recombitant human insulin
- 10mL Vial
- Aqueous suspension
- First protamine zinc insulin approved by the FDA specifically for use in cats
RX required for this item.
Click here for our full Prescription Policy and Form
PROZINC: understanding insulin PROZINC™ (protamine zinc recombinant human insulin) Receives FDA Approval ProZinc.
What insulin is, and what it does
For some cats with diabetes, lifestyle changes such as an exercise plan and a special diet may be the only treatment they need. But most cats with diabetes also need insulin injections.
Insulin is important for regulating a cat's blood glucose (sugar), which is a critical metabolic process. Healthy cats can produce all the insulin they need on their own. Some cats with diabetes must get the insulin they need another way — through insulin injections.
Why PROZINC is special
PROZINC is a protamine zinc insulin, a type of long-acting insulin that is ideal for your cat's condition. Protamine zinc insulin releases slowly over time to better maintain a stable, consistent blood glucose level throughout the day.
PROZINC is the first protamine zinc insulin that is approved by the FDA specifically for use in cats.
The safety and effectiveness of PROZINC insulin in kittens and in breeding, pregnant, and lactating cats has not been evaluated. Use of this product, even at established doses, has been associated with hypoglycemia.1 An animal with signs of hypoglycemia should be treated immediately. See Safety Info page for more information.
The PROZINC syringe
When you give your cat a PROZINC injection, make sure you use the correct type of syringe. PROZINC is a U-40 insulin, meaning that there are 40 units of insulin per milliliter (ml) of product. That is why PROZINC must be injected with a U-40 syringe. This is very important because using another type of syringe will deliver the wrong dose.
How to fill the syringe
1. The syringe is marked with numbers indicating units of PROZINC. Be sure to give your cat the number of units prescribed by your veterinarian. NOTE: Do not try to adjust your cat's dosage without your veterinarian's supervision.
2. Remove the caps from the plunger and needle, and pull back the plunger to the prescribed dose of PROZINC.
3. Gently roll the PROZINC vial between your hands. This step mixes the insulin and also warms it so the injection will be more comfortable for your cat. NOTE: It is important that you roll the vial, and not shake it. Shaking the vial may reduce the effect of the insulin by breaking the insulin molecules apart.
4. Insert the needle into the top of the PROZINC vial and push the plunger all the way in to inject air into the vial.
5. Now turn the vial upside-down with the needle still inserted. Make sure the tip of the needle is submerged in the insulin. Pull back the plunger a few units past the prescribed dose. Keep the needle inserted in the vial.
6. Look for large air bubbles in the syringe. If you see any, gently tap the side of the syringe with your finger to release them.
7. Now gently push the plunger back in to the prescribed dose. Take your finger off of the plunger and withdraw the needle from the vial.
Now you're ready to give the injection.
It is best to give your cat's PROZINC injections at feeding time or just afterward. It is also best to give the injections at the same time every day, because it will help your cat maintain the most stable blood glucose levels. This will be easier to do if you stick closely to your feeding schedule.
The easy way to give your cat an injection
Injecting your cat with PROZINC might sound scary and seem like a hard thing to do, but it's really not. Your veterinarian will show you how, and you can also follow the instructions below. With a little practice, PROZINC injections will become easy for you and your cat.
1. Place your cat on a stable surface.
2. Take a moment to pet your cat! It's best if you and your cat are calm while you give the injection.
3. While you're petting your cat, gently pull up a fold of skin on your cat's neck or side. Don't use the same spot each time.
4. Quickly insert the needle into the fold of skin. The insulin needle is very thin and sharp. It won't hurt your cat, especially if you insert it quickly.
5. Pull the plunger back slightly to ensure no blood enters the syringe. If you see any blood in the syringe, discard it and start over with a new syringe.
6. Gently push the plunger all the way in, pull out the needle, and reward your cat with more petting.
7. Dispose of the syringe in a sharps container.
8. Store PROZINC in the refrigerator. PROZINC should be stored at a temperature between 36° and 46° F.
If you are not sure the dose was completely delivered, it is important to not give another dose. It is better to err on the side of underdosing your cat with insulin, not overdosing.
User safety warnings
For use in cats only. Keep out of the reach of children. Avoid contact with eyes. In case of contact, immediately flush eyes with running water for at least 15 minutes. Accidental injection may cause hypoglycemia. In case of accidental injection, seek medical attention immediately. Exposure to product may induce a local or systemic allergic reaction in sensitized individuals. See Safety Info page for more information.
Because this is a cooler item, it must Ship OVERNIGHT Delivery to insure the integrity of the product. This items ships in a styrofoam cooler with ice packs on Monday-Thursdays (on orders placed before 2:00p.m.)
Click here for our Vaccine Shipping Schedule.
(protamine zinc recombinant human insulin)
NADA 141-297, Approved by FDA
Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Description: ProZinc™ insulin is a sterile aqueous protamine zinc suspension of recombinant human insulin.
Each mL contains:
recombinant human insulin
40 International Units (IU)
dibasic sodium phosphate, heptahydrate
phenol (added as preservative)
water for injection (maximum)
pH is adjusted with hydrochloric acid and/or sodium hydroxide.
Indications: ProZinc (protamine zinc recombinant human insulin) is indicated for the reduction of hyperglycemia and hyperglycemia-associated clinical signs in cats with diabetes mellitus.
Dosage and Administration: USE OF A SYRINGE OTHER THAN A U-40 SYRINGE WILL RESULT IN INCORRECT DOSING.
FOR SUBCUTANEOUS INJECTION IN CATS ONLY.
ProZinc insulin should be mixed by gently rolling the vial prior to withdrawing each dose from the vial. Using a U-40 insulin syringe, the injection should be administered subcutaneously on the back of the neck or on the side of the cat.
Always provide the Cat Owner Information Sheet with each prescription. The initial recommended ProZinc dose is 0.1 - 0.3 IU insulin/pound of body weight (0.2 - 0.7 IU/kg) every 12 hours. The dose should be given concurrently with or right after a meal. The veterinarian should re-evaluate the cat at appropriate intervals and adjust the dose based on both clinical signs and glucose nadirs until adequate glycemic control has been attained. In the effectiveness field study, glycemic control was considered adequate if the glucose nadir from a 9-hour blood glucose curve was between 80 and 150 mg/dL and clinical signs of hyperglycemia such as polyuria, polydipsia, and weight loss were improved.
Further adjustments in the dosage may be necessary with changes in the cat’s diet, body weight, or concomitant medication, or if the cat develops concurrent infection, inflammation, neoplasia, or an additional endocrine or other medical disorder.
Contraindications: ProZinc insulin is contraindicated in cats sensitive to protamine zinc recombinant human insulin or any other ingredients in the ProZinc product. ProZinc insulin is contraindicated during episodes of hypoglycemia.
Warnings: User Safety: For use in cats only. Keep out of the reach of children. Avoid contact with eyes. In case of contact, immediately flush eyes with running water for at least 15 minutes. Accidental injection may cause hypoglycemia. In case of accidental injection, seek medical attention immediately. Exposure to product may induce a local or systemic allergic reaction in sensitized individuals.
Animal Safety: Owners should be advised to observe for signs of hypoglycemia (see Cat Owner Information Sheet). Use of this product, even at established doses, has been associated with hypoglycemia. An animal with signs of hypoglycemia should be treated immediately. Glucose should be given orally or intravenously as dictated by clinical signs. Insulin should be temporarily withheld and, if indicated, the dosage adjusted.
Any change in insulin should be made cautiously and only under a veterinarian’s supervision. Changes in insulin strength, manufacturer, type, species (human, animal) or method of manufacture (rDNA versus animal-source insulin) may result in the need for a change in dosage.
Appropriate diagnostic tests should be performed to rule out other endocrinopathies in diabetic cats that are difficult to regulate.
Precautions: Animals presenting with severe ketoacidosis, anorexia, lethargy, and/or vomiting should be stabilized with short-acting insulin and appropriate supportive therapy until their condition is stabilized. As with all insulin products, careful patient monitoring for hypoglycemia and hyperglycemia are essential to attain and maintain adequate glycemic control and to prevent associated complications. Overdosage can result in profound hypoglycemia and death. Progestogens, certain endocrinopathies and glucocorticoids can have an antagonistic effect on insulin activity. Progestogen and glucocorticoid use should be avoided.
Reproductive Safety: The safety and effectiveness of ProZinc insulin in breeding, pregnant, and lactating cats has not been evaluated.
Use in Kittens: The safety and effectiveness of ProZinc insulin in kittens has not been evaluated.
Adverse Reactions: Effectiveness Field Study
In a 45-day effectiveness field study, 176 cats received ProZinc insulin. Hypoglycemia (defined as a blood glucose value of < 50 mg/dL) occurred in 71 of the cats at various times throughout the study. Clinical signs of hypoglycemia were generally mild in nature (described as lethargic, sluggish, weak, trembling, uncoordinated, groggy, glassy-eyed or dazed). In 17 cases, the veterinarian provided oral glucose supplementation or food as treatment. Most cases were not associated with clinical signs and received no treatment. One cat had a serious hypoglycemic event associated with stupor, lateral recumbency, hypothermia and seizures. All cases of hypoglycemia resolved with appropriate therapy and if needed, a dose reduction.
Three cats had injection site reactions which were described as either small, punctate, red lesions; lesions on neck; or palpable subcutaneous thickening. All injection site reactions resolved without cessation of therapy.
Four cats developed diabetic neuropathy during the study as evidenced by plantigrade stance. Three cats entered the study with plantigrade stance, one of which resolved by Day 45. Four cats were diagnosed with diabetic ketoacidosis during the study. Two were euthanized due to poor response to treatment. Five other cats were euthanized during the study, one of which had hypoglycemia. Four cats had received ProZinc insulin for less than a week and were euthanized due to worsening concurrent medical conditions.
The following additional clinical observations or diagnoses were reported in cats during the effectiveness field study: vomiting, lethargy, diarrhea, cystitis/hematuria, upper respiratory infection, dry coat, hair loss, ocular discharge, abnormal vocalization, black stool, and rapid breathing.
Extended Use Field Study
Cats that completed the effectiveness study were enrolled into an extended use field study. In this study, 145 cats received ProZinc insulin for up to an additional 136 days. Adverse reactions were similar to those reported during the 45-day effectiveness study and are listed in order of decreasing frequency: vomiting, hypoglycemia, anorexia/poor appetite, diarrhea, lethargy, cystitis/hematuria, and weakness. Twenty cats had signs consistent with hypoglycemia described as: sluggish, lethargic, unsteady, wobbly, seizures, trembling, or dazed. Most of these were treated by the owner or veterinarian with oral glucose supplementation or food; others received intravenous glucose. One cat had a serious hypoglycemic event associated with seizures and blindness. The cat fully recovered after supportive therapy and finished the study. All cases of hypoglycemia resolved with appropriate
therapy and if needed, a dose reduction.
Fourteen cats died or were euthanized during the extended use study. In two cases, continued use of insulin despite anorexia and signs of hypoglycemia contributed to the deaths. In one case, the owner decided not to continue therapy after a presumed episode of hypoglycemia. The rest were due to concurrent medical conditions or worsening of the diabetes mellitus.
To report suspected adverse reactions, or to obtain a copy of the Material Safety Data Sheet (MSDS), call 1-866-638-2226.
Information for Cat Owners: Please refer to the Cat Owner Information Sheet for more information about ProZinc insulin. ProZinc insulin, like other insulin products, is not free from adverse reactions. Owners should be advised of the potential for adverse reactions and be informed of the associated clinical signs. Potential adverse reactions include: hypoglycemia, insulin antagonism/resistance, rapid insulin metabolism, insulin-induced hyperglycemia (Somogyi Effect), and local or systemic reactions. The most common adverse reaction observed is hypoglycemia. Signs may include: weakness, depression, behavioral changes, muscle twitching, and anxiety. In severe cases of hypoglycemia, seizures and coma can occur.
Hypoglycemia can be fatal if an affected cat does not receive prompt treatment. Appropriate veterinary monitoring of blood glucose, adjustment of insulin dose and regimen as needed, and stabilization of diet and activity help minimize the risk of hypoglycemic episodes. The attending veterinarian should evaluate other adverse reactions on a case-by-case basis to determine if an adjustment in therapy is appropriate, or if alternative therapy should be considered.
Effectiveness: A total of 187 client-owned cats were enrolled in a 45-day field study, with 176 receiving ProZinc insulin. One hundred and fifty-one cats were included in the effectiveness analysis. The patients included various purebred and mixed breed cats ranging in age from 3 to 19 years and in weight from 4.6 to 20.8 pounds. Of the cats included in the effectiveness analysis, 101 were castrated males, 49 were spayed females, and 1 was an intact female.
Cats were started on ProZinc insulin at a dose of 0.1-0.3 IU/lb (0.2-0.7 IU/kg) twice daily. Cats were evaluated at 7, 14, 30, and 45 days after initiation of therapy and the dose was adjusted based on clinical signs and results of 9-hour blood glucose curves on Days 7, 14, and 30.
Effectiveness was based on successful control of diabetes which was defined as improvement in at least one blood glucose variable (glucose curve mean, nadir, or fructosamine) and at least one clinical sign (polyuria, polydipsia, or body weight). Based on this definition, 115 of 151 cases (76.2%) were considered successful. Blood glucose curve means decreased from 415.3 mg/dL on Day 0 to 203.2 mg/dL by Day 45 and the mean blood glucose nadir decreased from 407.9 mg/dL on Day 0 to 142.4 mg/dL on Day 45. Mean fructosamine values decreased from 505.9 µmol/L on Day 0 to 380.7 µmol/L on Day 45.
Cats that completed the effectiveness study were enrolled in an extended use field study. The mean fructosamine value was 342.0 µmol/L after a total of 181 days of ProZinc therapy.
How Supplied: ProZinc insulin is supplied as a sterile injectable suspension in 10 mL multidose vials. Each mL of ProZinc product contains 40 IU recombinant human insulin.
Storage Conditions: Store in an upright position under refrigeration at 36-46°F (2-8°C). Do not freeze. Protect from light.
Manufactured for: Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO 64506 U.S.A.
Manufactured by: AAIPharma, Charleston, SC 29405
ProZinc™ is a trademark of Boehringer Ingelheim Vetmedica, Inc.
© 2009 Boehringer Ingelheim Vetmedica, Inc. All Rights Reserved.
NAC No.: 10281750